Clinical Investigation of Buttermere (LENS 271) Soft Contact Lenses

The purpose of the study is to compare clinical performance between two soft contact lenses.

Study Overview

• Status: Completed
• Conditions: Myopia
• Intervention / Treatment: Device: Test Lenses (stenfilcon A); Device: Control Lenses (omafilcon A)

Detailed Description

The purpose of this study is to compare clinical performance of two soft contact lenses in a crossover study over a period of 7 days of wear.

• Study Type: Interventional
• Enrollment (Actual): 73
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom, SW1E 6AU
    • Ocular Technology Group - International

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

i. Age 8 to 18 years; at least half the population will be children or adolescents aged 8 to 15 years.

ii. Have experience with soft contact lens wear and able to insert and remove soft contact lenses.

iii. Parent/guardian and participant have read and understood the Participant Information Sheet.

iv. Parent/guardian and participant have read, signed and dated the Informed Consent and Assent (when applicable).

v. Best corrected visual acuity of at least 20/25 in each eye.

vi. Have normal eyes with the exception of the need for visual correction.

vii. Spectacle refraction:

• Age 8 to 12: -0.75D to -4.00D spherical equivalent, with cylinder ≤ -0.75D and maximum anisometropia of <1.00D
• Age 13-18: -0.75D to -7.00D spherical equivalent, with cylinder ≤ -0.75D and maximum anisometropia of <1.00D.

viii. Be willing and able to adhere to the instructions set in the clinical protocol and maintain the appointment schedule.

Exclusion Criteria:

i. Acute and subacute inflammation or infection of the anterior chamber of the eye.

ii. Any eye disease, injury, or abnormality that affects the cornea, conjunctiva, or eyelids.

iii. Severe insufficiency of lacrimal secretion (dry eyes).

iv. Corneal hypoesthesia (reduced corneal sensitivity), if not aphakic.

v. Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses.

vi. Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or use of contact lens solutions.

vii. Any active corneal infection (bacterial, fungal, or viral).

viii. The patient is unable to follow lens handling and wear regimen or unable to obtain assistance to do so.

ix. Newly prescribed use of systemic or ocular medications for which contact lens wear could be contraindicated as determined by the investigator.

x. Monocular participants (only one eye with functional vision) or participants fit with only one lens.

xi. Subjects with slit lamp findings greater than grade 1 (e.g., edema, infiltrates, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival, anterior segment inflammation) as per ISO 11980:2012, any previous history or signs of a contact lens related corneal inflammatory event (past corneal ulcers), or any other ocular abnormality that may contraindicate contact lens wear at the enrolment visit.

xii. History of herpetic keratitis, ocular surgery or irregular cornea.

xiii. Enrolment of the family members of the investigator, family members of the investigator's staff, or individuals living in the households of these individuals.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Test Lenses, Then Control Lenses; Participants will wear the Test Lenses in both eyes for one week and then cross over to the Control Lenses in both eyes for one week.	Device: Test Lenses (stenfilcon A); Daily disposable, soft contact lenses worn for one week; Device: Control Lenses (omafilcon A); Daily disposable, soft contact lenses worn for one week
Experimental: Control Lenses, Then Test Lenses; Participants will wear the Control Lenses in both eyes for one week and then cross over to the Test Lenses in both eyes for one week.	Device: Test Lenses (stenfilcon A); Daily disposable, soft contact lenses worn for one week; Device: Control Lenses (omafilcon A); Daily disposable, soft contact lenses worn for one week

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total Absolute Decentration	Total absolute decentration from pupil centre in mm at one-week follow-up visits after at least three hours of wear. Decentration for the eye in primary position (relaxed, looking straight ahead) will be measured on three-point scale where 0= optimal lens centration , 1 = acceptable decentration and 2= unacceptable decentration.	At the end of one week daily disposable wear, after at least three hours of wear.
Contact Lens Centration	Contact lens centration clinical rating at one-week follow-up visits after at least three hours of wear. Centration for the eye in primary position (relaxed, looking straight ahead) will be measured on three-point scale where 0= optimal lens centration, 1 = acceptable decentration and 2= unacceptable decentration.	At the end of one week daily disposable wear, after at least three hours of wear.
Contact Lens Movement	Contact lens movement at blink clinical rating at one-week follow-up visits after at least three hours of wear. Contact Lens Movement will be recorded: a) for the eye in the primary position immediately after the blink; b) for the recovery movement following digitally applied lower lid margin push-up with the lower lid as follows: (-2) = reduced movement unacceptable (-1) = reduced movement acceptable (0) = optimal movement (+1) = excessive movement acceptable (+2) = excessive movement unacceptable	At the end of one week daily disposable wear, after at least three hours of wear.

Collaborators and Investigators

• Sponsor: CooperVision, Inc.
• Investigators: Principal Investigator: Michel Guillon, PhD, Ocular Technology Group- International

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2024
• Primary Completion (Actual): March 5, 2025
• Study Completion (Actual): March 5, 2025

Study Registration Dates

• First Submitted: September 20, 2024
• First Submitted That Met QC Criteria: September 20, 2024
• First Posted (Actual): September 23, 2024

Study Record Updates

• Last Update Posted (Actual): February 24, 2026
• Last Update Submitted That Met QC Criteria: February 20, 2026
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Refractive Errors; Myopia
• Other Study ID Numbers: CV-23-02

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes